Business Context and Reporting Period
This Form 8-K Current Report was filed by Bristol-Myers Squibb Company on March 8, 2016, regarding an event dated March 3, 2016. The filing addresses Item 5.02, concerning the election of a new director and associated compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes
The Board of Directors elected Peter J. Arduini as a new member, effective April 1, 2016. Consequently, the size of the Board of Directors was increased to twelve members. Mr. Arduini is currently the President and CEO of Integra LifeSciences Holdings Corporation and has been determined to be independent under NYSE Listing Standards.
Guidance, Outlook, and Management Commentary
Mr. Arduini will serve on the Audit Committee effective May 3, 2016, and will stand for election by shareholders at the Annual Meeting expected on May 3, 2016. There are no related party transactions between the Company and Mr. Arduini. His compensation includes:
- An annual retainer of $100,000.
- An annual award of deferred share units valued at $170,000 on the date of grant (with a pro rata portion for 2016).
- An additional annual retainer of $15,000 for Audit Committee service.
Important Facts for Investor Verification
- Confirmation of the Board size increase to twelve members.
- Verification of Mr. Arduini's independence status and lack of related party transactions.
- Details of the specific deferred share unit grant value and pro rata calculation for 2016.
- Confirmation of the May 3, 2016, date for the Annual Meeting of Shareholders.